泽璟制药：收到《药物临床试验批准通知书》

Group 1 - The core point of the article is that Zai Lab has received approval from the National Medical Products Administration for a clinical trial of ZG005 in combination with Jikaxitinib and chemotherapy for advanced solid tumors [2] Group 2 - The clinical trial approval indicates a significant step forward for Zai Lab in its oncology pipeline, potentially enhancing its market position in cancer treatment [2]